Author:
Gorgal Tiago,Charrua Ana,Silva João F,Avelino António,Dinis Paulo,Cruz Francisco
Abstract
Abstract
Background
Onabotulinumtoxin A (OnabotA) injection has been investigated as a novel treatment for benign prostatic enlargement caused by benign prostatic hyperplasia. An OnabotA - induced volume reduction caused by sympathetic fibers impairment has been proposed as a potential mechanism of action. Our aim was to investigate the expression of apoptosis-regulating proteins in the rat prostate following OnabotA intraprostatic injection.
Methods
Adult Wistar rats were injected in the ventral lobes of the prostate with 10 U of OnabotA or saline. A set of OnabotA-injected animals was further treated with 0.5 mg/kg of phenylephrine (PHE) subcutaneously daily. All animals were sacrificed after 1 week and had their prostates harvested. Immunohistochemical staining was performed for Bax, Bcl-xL and caspase-3 proteins and visualized by the avidin-biotin method. The optical density of the glandular cells was also determined, with measurement of differences between average optical densities for each group.
Results
Saline-treated animals showed intense epithelial staining for Bcl-xL and a faint labelling for both Bax and Caspase-3. OnabotA-treated rats showed a reduced epithelial staining of Bcl-xL and a consistently increased Bax and Caspase-3 staining when compared with saline-treated animals. PHE-treated animals showed a stronger Bcl-xL staining and reduced staining of both Bax and Caspase-3 when compared to the OnabotA group. Mean signal intensity measurements for each immunoreaction confirmed a significant decrease of the signal intensity for Bcl-xL and a significant increase of the signal intensity for Bax and Caspase 3 in OnabotA-injected animals when compared with the control group. In OnabotA+PHE treated animals mean signal intensity for Bcl-xL, Bax and Caspase 3 immunoreactions was identical to that of the control animals.
Conclusions
These results support the hypothesis that OnabotA activates apoptotic pathways in the rat prostate through a mechanism that involves sympathetic outflow impairment.
Publisher
Springer Science and Business Media LLC
Subject
Urology,Reproductive Medicine,General Medicine
Reference30 articles.
1. Chuang YC, Kuo HC, Chancellor MB: Botulinum toxin for the lower urinary tract. BJU Int. 2010, 105: 1046-1058. 10.1111/j.1464-410X.2010.09317.x.
2. Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA: Botox-induced prostatic involution. Prostate. 1998, 37: 44-50. 10.1002/(SICI)1097-0045(19980915)37:1<44::AID-PROS7>3.0.CO;2-8.
3. Chuang YC, Tu CH, Huang CC, Lin HJ, Chiang PH, Yoshimura N, Chancellor MB: Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. BMC Urol. 2006, 18: 6-12.
4. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A: Relief of botulinum toxin of voiding disfunction due to benign prostatic hyperplasia: results of randomized, placebo-controlled study. Urology. 2003, 62: 259-264. 10.1016/S0090-4295(03)00477-1.
5. Silva J, Silva C, Saraiva L, Silva A, Pinto R, Dinis P, Cruz F: Intraprostatic botulinum toxin type A injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur Urol. 2008, 53: 153-159. 10.1016/j.eururo.2007.08.050.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献